News und Analysen
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced the presentation of new data on lebrikizumab through 18 abstracts, including two oral
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023
ICON Secures Upgraded Credit Rating from S&P Global Ratings
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Poxel Announces its Participation at Upcoming Investor Conferences
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25
Chemed To Report Third-Quarter 2023 Earnings October 25, Related Conference Call To Be Held On October 26
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2023, on Wednesday, October 25, 2023, following the close of trading
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environmental goals, the Company has achieved 90 percent renewable
Premier, Inc. to Report Fiscal 2024 First-Quarter Results and Host Conference Call on November 7, 2023
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 first quarter on Tuesday, November 7, 2023, at approximately 6:30 a.m. ET. The company will
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that
Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2023 financial
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone